Pfizer, Novartis, and Shire are among nearly a dozen biopharma companies, research institutions, and developers building a combined 3.5 million plus square feet of lab and office space totaling more than $2 billion across Massachusetts. The list also includes research institutions like Broad Institute and developers like Alexandria Real Estate Equities. While companies are growing, with aided incentives like tax breaks, Massachusetts will face increasing competition from global emerging markets with their own incentives such as lower wages and less regulatory red tape.

Poll Question:
How confident are you that Massachusetts can sustain its biopharma construction boom?

Very
38

Somewhat
15

Not Very
7

Undecided
3

Previous articleLawmaker Criticizes Continued Development of Pure-Hydrocodone Drugs
Next articleAmeritox Gains Exclusive Rights to Ridge Diagnostics’ Depression Test